¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

½ÉÀå´ë»çÁõÈıºÇÐȸ 2021 Ãß°è½ÉÆ÷Áö¾ö : 2021-09-25

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
½ÉÀå´ë»çÁõÈıºÇÐȸ 2021 Ãß°è½ÉÆ÷Áö¾ö : 2021-09-25
±³À°ÀÏÀÚ : 2021-09-25
±³À°Àå¼Ò : ½ºÀ§½º±×·£µåÈ£ÅÚ Flamingo Room  
±³À°ÁÖÁ¦ : ½ÉÀå´ë»çÁõÈıºÇÐȸ 2021 Ãß°è½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ½ÉÀå´ë»çÁõÈıºÇÐȸ  
´ã´çÀÚ : ¿À¼öÇö
¿¬¶ôó : 032-460-0000  
À̸ÞÀÏ : apcms@kscms.org      
±³À°Á¾·ù : ³»°ú¿¹¹æÀÇÇÐ, ÀÇÇб³À°
Âü¼®¿¹»óÀοø : 70¸í
Èñ¸ÁÆòÁ¡ : 5Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 25ºÐ  
¼¼ºÎ¼ö°­·á : 40,000¿ø      
ºñ°í ±³¼ö ¹× °³¿øÀÇ 4¸¸¿ø / Àü°øÀÇ, ÀüÀÓÀÇ, ±âŸ 2¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-25 Flamingo 09:00~09:15 TG variability  ¹Ú»ó¹Î(À»ÁöÀÇ´ë ¼øȯ±â³»°ú) 
±³À°½Ã°£ 09-25 Flamingo 09:15~09:30 BP variability  ±èÇзÉ(¼­¿ïÀÇ´ë º¸¶ó¸Åº´¿ø ¼øȯ±â³»°ú) 
±³À°½Ã°£ 09-25 Flamingo 09:30~09:45 Glucose variability  ¿ÀÅÂÁ¤(ºÐ´ç¼­¿ï´ë ¼øȯ±â³»°ú) 
Åä·Ð 09-25 Flamingo 09:45~10:05 Discussion  All Panellist() 
È޽Ġ09-25 Flamingo 10:05~10:45 Coffee Break & Photo Time  () 
±³À°½Ã°£ 09-25 Flamingo 10:45~11:00 µðÁöÅÐÇコ_ ÆÐÄ¡Çü 12-Àü±Ø ½ÉÀüµµ È°¿ë  Â÷¿øö(»ï¼º¼­¿ïº´¿ø ÀÀ±ÞÀÇÇаú) 
±³À°½Ã°£ 09-25 Flamingo 11:00~11:15 µðÁöÅÐÇコ_ »ýü½ÅÈ£ ±â¹Ý, ÀΰøÁö´É CDSS  À±´ö¿ë(¿¬¼¼´ëÇб³ ÀÇ»ý¸í½Ã½ºÅÛÁ¤º¸Çб³½Ç) 
±³À°½Ã°£ 09-25 Flamingo 11:15~11:30 ºñ´ë¸éÁø·á_ ±Ù°Å ±â¹ÝÀÇ ÀÓ»óÈ°¿ë  ±èÇ强(°¡Å縯´ëÇб³ ÀÇ·áÁ¤º¸Çб³½Ç ¼­¿ï¼º¸ðº´¿ø ³»ºÐºñ³»°ú) 
±³À°½Ã°£ 09-25 Flamingo 11:30~11:45 ºñ´ë¸éÁø·á_ ÀÓ»óÈ°¿ë »ç·Êº° ¹ýÀû ÀïÁ¡  À¯ÁöÇö(¹ý¹«¹ýÀÎ ±¤Àå) 
Åä·Ð 09-25 Flamingo 11:45~12:05 Discussion  All Panellist() 
±³À°½Ã°£ 09-25 Flamingo 12:05~12:20 Are all statins the same?  ÃÖö¿õ(°í´ë±¸·Îº´¿ø ¼øȯ±â³»°ú) 
±³À°½Ã°£ 09-25 Flamingo 12:20~12:35 Sevikar HCT, Who Will Benefit From It?  ¹®Á¤±Ù(°¡ÃµÀÇ´ë ½ÉÀå³»°ú) 
½Ä»ç 09-25 Triangle Foyer 12:35~13:35 Lunch  () 
±³À°½Ã°£ 09-25 Flamingo 13:35~13:50 Metabolic syndrome severity score for predicting cardiovascular events  ÇãÁöÇý(ÇѸ²ÀÇ´ë ³»ºÐºñ³»°ú) 
±³À°½Ã°£ 09-25 Flamingo 13:50~14:05 Associations between metabolic syndrome and type of dementia  ±è¿©Áø(ÃáõÇѸ²´ëº´¿ø ³»ºÐºñ³»°ú) 
±³À°½Ã°£ 09-25 Flamingo 14:05~14:20 Metabolic syndrome and incidence of gastric cancer in Korea  ±èÇü¼ö(°Ç±¹´ë¿¹¹æÀÇÇаú±³½Ç) 
Åä·Ð 09-25 Flamingo 14:20~14:40 Discussion  All Panellist() 
±³À°½Ã°£ 09-25 Flamingo 14:40~14:55 STRENGTH Trial and its post hoc analysis and cuurent status of EPA  ¼ÕÁ¤¿ì(¿øÁÖÀÇ´ë ½ÉÀå³»°ú) 
±³À°½Ã°£ 09-25 Flamingo 14:55~15:10 A Phase2 Trial Of The Efficacy And Safety Of Evinacumab In Patients With Severe Hypertriglyceridemia  À念¿ì(°¡ÃµÀÇ´ë ½ÉÀå³»°ú) 
±³À°½Ã°£ 09-25 Flamingo 15:10~15:25 Inpatient Use of Continuous Glucose Monitoring to Improve Hyperglycemia and prevent hypoglycemia  ¹Ú¼¼Àº(°­ºÏ»ï¼º ³»ºÐºñ³»°ú) 
±³À°½Ã°£ 09-25 Flamingo 15:25~15:40 Tracking the CV impact of SGLT-2 inhibitors: A guide to use SGLT2-inhibitors in Clinical Practice  È«ÁØÈ­(À»ÁöÀÇ´ë ³»ºÐºñ³»°ú) 
Åä·Ð 09-25 Flamingo 15:40~16:00 Discussion  All Panellist() 
È޽Ġ09-25 Flamingo 16:00~16:20 Coffee Break & Photo Time  () 
±³À°½Ã°£ 09-25 Flamingo 16:20~16:35 »ýÈ° ¿ä¹ý 1- Èí¿¬, À½ÁÖ, üÁß  À̹ÎÈ£(¼øõÇâ ¼­¿ïº´¿ø ¼øȯ±â³»°ú) 
±³À°½Ã°£ 09-25 Flamingo 16:35~16:50 »ýÈ° ¿ä¹ý 2- ½Ä»ç, ¿îµ¿, ÀÎÁöÇൿ  ±èÁöÇý(µ¿±¹´ëº´¿ø ¼øȯ±â³»°ú) 
±³À°½Ã°£ 09-25 Flamingo 16:50~17:05 ´ë»çÁõÈıºÀÇ Ç÷¾Ð, ÁöÁú, Ç÷´ç °ü¸®  Á¤ÀçÈÆ(±¹¸³ÀÇ·á¿ø ¼øȯ±â³»°ú) 
Åä·Ð 09-25 Flamingo 17:05~17:25 Discussion  All Panellist() 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ½ÉÀå´ë»çÁõÈıºÇÐȸ 2021 Ãß°è½ÉÆ÷Áö¾ö : 2021-09-25""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û [¿Â¶óÀÎ] Á¦6ȸ µÎ°æºÎÃÊÀ½ÆÄ ¼¼¹Ì³ª : 2021-09-26
´ÙÀ½±Û (¿Â¶óÀÎ) 2021³â ´ëÇÑÁ¾¾ç¿Ü°úÇÐȸ ¿¬¼ö°­Á : 2021-09-25
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20805 ¼­¿ï 2024 ´ëÇÑ»ê°ú¸¶ÃëÇÐȸ Á¦27Â÷ Çмú´ëȸ : 2024-06-15 0 4 2024-05-27
20804 ÃæºÏ 204 ÃæûºÏµµÀÇ»çȸ Ãá°è Çмú´ëȸ : 2024-06-15 0 8 2024-05-27
20803 ºÎ»ê 2024³â Á¦7ȸ ´ëÇÑÁßȯÀÚÀçÈ°ÇÐȸ Áý´ãȸ : 2024-06-15 0 3 2024-05-27
20802 ºÎ»ê 2024³â ´ëÇÑÁßȯÀÚÀçÈ°ÇÐȸ ¿öÅ©¼¥-±â´ÉÀû Æò°¡ ¹× ÁßȯÀÚ ÀçÈ°ÀÇ ½ÇÁ¦ (¿Ü»ó ÁßȯÀÚ Æ÷ÇÔ) : 2024-06-15 0 6 2024-05-27
20801 ¼­¿ï KLASS 20Áֳ⠱â³ä 2024 ´ëÇѺ¹°­°æÀ§Àå°ü¿¬±¸È¸ Á¦27ȸ Á¤±âÇмú´ëȸ : 2024-06-15 0 3 2024-05-27
20800 °æ±â 2024³â Á¦ 3ȸ Áß¾Ó´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç °³¿øÀÇ ¿¬¼ö°­Á : 2024-06-15 0 8 2024-05-27
20799 ¼­¿ï (¿Â¶óÀÎ) 2024³âµµ ÀÓ»óÁø·áÁöħ Æò°¡À§¿ø ¾ç¼º±³À° : 2024-06-15 0 3 2024-05-27
20798 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼҾÆû¼Ò³â°ú ºÐ°úÀü¹®ÀÇ ¿¬¼ö±³À° : 2024-06-15 0 1 2024-05-27
20797 ¼­¿ï ´ëÇÑ°áÇÙ¹×È£Èí±âÇÐȸ COPD School 2024 : 2024-06-15 0 1 2024-05-27
20796 ¼­¿ï »óóÀå·ç¿¬±¸È¸ Áý´ãȸ : 2024-06-15 0 2 2024-05-27
20795 Àü³² 2024³â Àü¶ó³²µµÀÇ»çȸ Àü¹Ý±â Çмú´ëȸ : 2024-06-15 0 3 2024-05-27
20794 ¼­¿ï Ç÷°ü¿µ»ó»ý¸®¿¬±¸È¸ IPOP(Imaging and Physiology on Patients with Cardiovascular Disease) 2024 : 2024-06-15 0 1 2024-05-27
20793 ¼­¿ï ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ ¾à¹°¾Ë·¹¸£±â ½ÉÆ÷Áö¾ö : 2024-06-15 0 4 2024-05-27
20792 ´ëÀü ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ ´ëÀü, ÃæûÁöȸ - Á¦3Â÷ ¿ù·ÊÁý´ãȸ : 2024-06-15 0 1 2024-05-27
20791 ¼­¿ï Á¦51ȸ ´ëÇÑÀÓ»óÇǺÎÄ¡·á¿¬±¸È¸ ±³À°½ÉÆ÷Áö¾ö : 2024-06-15 0 5 2024-05-27
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷